Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)

NCT05996263 · clinicaltrials.gov ↗

UNKNOWN

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Stage III
Lung Cancer Stage IV

Sponsor

University Hospital, Brest